Study of TAK-733 in Combination With Alisertib in Adult Patients With Advanced Nonhematologic Malignancies

NCT01613261 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Advanced Nonhematologic Malignancies

Interventions

DRUG: TAK-733 and alisertib

Sponsor

Millennium Pharmaceuticals, Inc.